Branded PPI denied as not medically necessary by Aetna?

Aetna's specific coverage criteria for branded ppi are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Branded PPIs for Medical Necessity

Aetna's medical-necessity standard requires that a branded proton pump inhibitor (PPI) provide clinically meaningful benefit over generic alternatives for your specific condition. Most denials occur because the plan's clinical policy defaults to generic PPIs as therapeutically equivalent, so a branded product must clear an additional evidentiary bar. This denial is routinely overturned on appeal when the prescriber documents a clinically distinct reason the branded formulation is required.

## Federal Appeal Rights

Under ACA §2719 and its implementing regulations, non-grandfathered individual and fully-insured group plans must provide internal appeal rights followed by access to independent external review through an accredited IRO (independent review organization). If your plan is self-funded (ERISA), you have the right to a full-and-fair review under ERISA §503, and most states extend external review to ERISA plans by contract or regulation. The external-review request window is generally four months from the final internal denial — do not let that deadline pass. An expedited review (decision within 72 hours) is available if your condition is urgent or if the standard timeline could seriously jeopardize your health.

## Appeal Process and Timeline

1. Request the denial rationale in writing — Aetna must provide the specific clinical criteria it applied. 2. File the internal appeal within the plan's stated deadline (commonly 180 days from the denial notice). 3. Await the internal decision — plans must respond within 30 days for pre-service and 60 days for post-service appeals (expedited: 72 hours). 4. Escalate to external review if the internal appeal is upheld.

## Documentation to Gather

• Diagnosis confirmation: office notes, endoscopy/imaging reports, or other diagnostic records establishing the underlying condition (e.g., GERD, Barrett's esophagus, erosive esophagitis, H. pylori, NSAID-related ulcer prophylaxis).
• Prior-treatment history: a dated log of every generic PPI tried, the dose range, the duration of each trial, and the documented clinical outcome or adverse effect.
• Clinical severity: chart notes recording symptom burden, quality-of-life impact, or objective findings (e.g., pH-metry, endoscopic grade).
• Prescriber medical-necessity letter: a narrative explaining why the branded formulation is required — for example, a documented intolerance to an inactive ingredient present only in generic versions, demonstrated bioavailability difference, or formulary generic unavailability.

## Criteria-Mapping Strategy

Obtain Aetna's published Clinical Policy Bulletin for branded PPIs (available on aetna.com) and the FDA-approved prescribing label for the specific branded product. Create a two-column table: paste each listed criterion in the left column, and cite the exact chart fact or clinical record that satisfies it in the right column. Attach this table as a cover sheet to your appeal. Reviewers are required to apply only the criteria in the published policy — a point-by-point match makes denial difficult to sustain.